Aft banks on stronger second half as strike and destocking hit first-half result

Aft banks on stronger second half as strike and destocking hit first-half result
Hartley Atkinson says Aft should have a new licensing deal for its Maxigesic pain relief soon. (Image: Aft Pharmaceuticals)
Rebecca Stevenson
Aft Pharmaceuticals is pinning its hopes on a stronger second-half result after a $2.46 million loss for the six months to Sept 30. The New Zealand Exchange (NZX) listed pharmaceutical manufacturer said its result was affected by a doctor strike in South Korea and several large customers reducing stock. These caused a $6.5m hit to product sales and royalties in Aft’s Asian and other international markets, the company said.Sales of its Maxigesic intravenous line were significantly affected by the now-resolved doctors' strike....

More Markets

NZ sharemarket continues momentum, Skellerup sees green
Markets Market Close

NZ sharemarket continues momentum, Skellerup sees green

 The Red Band gumboot-maker said it earned $54.5m after tax. 

Tom Raynel 21 Aug 2025
Xero board faces 'first strike' over CEO pay
Markets

Xero board faces 'first strike' over CEO pay

Xero investors fire warning shot at directors willing to pay big for talent.

Staff reporters 21 Aug 2025
Auckland airport dynamics returning to normal
Markets

Auckland airport dynamics returning to normal

Yields are improving for airlines operating into Auckland, but earnings look flat ahead. 

Pattrick Smellie 21 Aug 2025